News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selcia Limited and NeuroVive Pharmaceutical AB to Develop New Mitochondrial Medicines for Chronic and Acute Diseases


9/19/2011 9:29:11 AM

ONGAR, England & LUND, Sweden--(BUSINESS WIRE)--UK-based contract research organisation Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB have signed a significant research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology. The collaboration is focused on mitochondrial medicine, an emerging therapeutic modality that promises innovative new treatments for major chronic diseases, such as cancer and obesity, and acute conditions such as stroke and heart failure. Selcia and NeuroVive will jointly invest in the collaboration to combine Selcia┬┤s leading expertise in medicinal and analytical chemistry, with NeuroVive┬┤s advanced research and development programs in mitochondrial medicine.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES